LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). "The liquid formulation and drug-device patents will provide protection in Europe through March 2041 and March. ...

Savara (NasdaqGS:SVRA) FY Conference December 02, 2025 02:30 PM ET Company ParticipantsBraden Parker - Chief Commercial OfficerMatt Pauls - CEOConference Call ParticipantsYasmeen Rahimi - Senior Biotech AnalystYasmeen RahimiPiper Sandler Healthcare Conference. My name is Yasmeen Rahimi. I'm a Senior Biotech Analyst at Piper. This is our five-year anniversary, Matt, as we're both at this healthcare conference, and I get to host you for a fireside chat. What can I say? An incredible journey over the five year ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, "Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.†The patent is jointly held by Savara and PARI and covers the combination of Savara's investigational therapy, MOLBREEVI, and PARI's investigationa. ...

Core Viewpoint - Rosen Law Firm is reminding investors of Savara Inc. (NASDAQ: SVRA) about the November 7, 2025 deadline to join a securities class action lawsuit related to the company's alleged misleading statements during the class period from March 7, 2024, to May 23, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by the November 7, 2025 deadline [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Savara Inc. - The lawsuit alleges that Savara made false and misleading statements regarding the MOLBREEVI Biologics License Application (BLA) for a treatment of a rare lung disease, including insufficient information on its chemistry and manufacturing [5]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became known [5].

Core Viewpoint - Savara Inc. is facing a federal securities class action due to allegations of misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI, which has led to significant investor losses [3][4]. Group 1: Allegations Against Savara - The complaint claims that Savara and its executives violated federal securities laws by making false or misleading statements about the MOLBREEVI BLA, including insufficient information regarding its chemistry and manufacturing [3]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [3]. - The public statements made by Savara were deemed materially false and misleading throughout the relevant period [3]. Group 2: Stock Price Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Legal Proceedings - Investors who suffered losses in Savara between March 7, 2024, and May 23, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal rights and options [1][5]. - The deadline for seeking the role of lead plaintiff in the class action is November 7, 2025 [1].

Core Viewpoint - Rosen Law Firm is encouraging investors of Savara Inc. to secure legal counsel before the November 7, 2025 deadline related to a securities class action lawsuit [1][2]. Group 1: Class Action Details - The class action pertains to Savara securities purchased between March 7, 2024, and May 23, 2025, with a lead plaintiff deadline set for November 7, 2025 [1]. - Investors who purchased Savara securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Savara made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [5]. - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that the public statements made by the defendants were materially false and misleading [5].

Core Viewpoint - Savara Inc. is facing a securities fraud class action lawsuit due to misleading statements regarding its Biologics License Application for MOLBREEVI, which led to significant stock price decline and investor losses [1][4][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Savara securities between March 7, 2024, and May 23, 2025, with a deadline of November 7, 2025, to participate as a lead plaintiff [1][5]. - The lawsuit alleges that Savara made materially false and misleading statements about its business and operations, particularly regarding the completeness of the MOLBREEVI BLA submission to the FDA [4][5]. - The FDA issued a refusal-to-file letter for the MOLBREEVI BLA on May 27, 2025, citing insufficient information, which led to a 31.7% drop in Savara's stock price, closing at $1.94 per share [2][3]. Group 2: Financial Impact - Following the FDA's refusal-to-file letter, Guggenheim lowered its price target for Savara, indicating potential delays in commercialization and the likelihood of additional capital raises [2][4]. - The lawsuit claims that the delay in regulatory approval for MOLBREEVI increased the likelihood of Savara needing to raise additional capital, further impacting investor confidence [4].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that during the class period from March 7, 2024, to May 23, 2025, Savara did not disclose that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely [8]. - The complaint also states that the delay in regulatory approval would likely necessitate Savara to raise additional capital [8]. - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [8]. Next Steps - Investors who purchased Savara shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5]. - The firm has offices in New York, California, and South Carolina [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Savara Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the November 7, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by November 7, 2025 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years, including over $438 million in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [5]. - It is claimed that the delay in regulatory approval would likely necessitate Savara to raise additional capital, and that the public statements made by the defendants were materially false and misleading [5].

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...